Background: Very few studies are conducted to compare the relative efficacy and safety of high-dose and low-dose oxytocin regimens on maternal outcomes. This study was aimed at comparing maternal outcomes of high-dose vs low-dose oxytocin regimen among pregnant mothers undergoing labor induction. Method and material: Comparative cross-sectional study was conducted in four selected hospitals of Ethiopian. All pregnant women fulfilling inclusion criteria were included. Collected data was entered into epidata version 3.1 and then exported to SPSS version 20 for cleaning and analysis. chi-square test, bivariate and multivariate logistic regression was done to look for association of independent variables with Adverse Maternal Outcomes (AMO). The result was presented using 95% Confidence Interval (CI) of Odds Ratios (OR). p-value<0.05 was used to declare statistical significance. Result: Mean average length of hospital stay was 2 days and 2.7 days among mothers receiving high dose oxytocin and low dose oxytocin regimen respectively. Of all maternal outcome variables only, puerperal sepsis was significantly related with oxytocin regimens with prevalence of 5.6% and 0% (X2=0.015, P=0.029) among low dose group and high dose group respectively. Misoprostol use for ripening [AOR 4.7, 95% CI 1.6, 13.4] and Neonatal birth weight of >4 kg [AOR 3.4, 95% CI 1.1, 10.3] were found to be associated with adverse maternal outcome. Conclusion: Oxytocin regimen has no significant association with adverse maternal outcome. However, low dose oxytocin use was associated with increased risk of puerperal sepsis and slightly longer duration of hospital stay.
Pregnancy during adolescence continues to be a frequent situation, mostly in developing countries. Maternal age is a key element to be taken into account when managing obstetric patients, as it is related with obstetric and perinatal outcomes. We conducted a literature review to address the obstetric results of pregnancy in teenage mothers. We reviewed articles for the last 5 years in different databases including ‘Pregnancy’, ‘Teenager’, ‘Adolescent’, ‘Complications’ and ‘Outcomes’ as key words. We obtained 2260 articles after the initial search, but only 28 met the inclusion criteria and were therefore reviewed. Most studies were excluded for not clearly specifying one of more groups of teenage patients, lacking comparison of these groups with no-teenage patients, or not addressing the obstetric outcomes of those pregnancies. The outcomes were divided into complications of pregnancy, childbirth, puerperium and neonatal complications. We found that there is an association between young maternal age and preterm birth, pre-eclampsia/eclampsia, fetal growth restriction and stillbirth, among others. For the newborn we found outcomes such as low APGAR scores and admission to intensive care were more frequent in teenage mothers. We conclude that maternal age is an important feature, as there are several obstetric and perinatal compications that are more frequent in teenage mothers than in other age groups.
Sextech, femtech, women’s health–regardless of the descriptor–is challenging. The barriers have been well-documented–challenges with fundraising for women-owned businesses, specific obstacles for fundraising for women’s sexual health businesses, especially those focused on pleasure and satisfaction, and lack of access to media channels.
Although the vast majority of patients with advanced-stage (stages III and IV) ovarian cancer will achieve a clinical complete response to primary treatment, a large percentage of those (approximately 80%) are at risk for recurrence of their ovarian cancer [1]. Currently, two Poly Aadenosine-diphosphate (ADP)-Ribose Polymerase (PARP) inhibitors, olaparib, and niraparib, are approved for advanced-stage maintenance therapy for BRCA mutated ovarian cancer after completion of first-line treatment. Those caring for patients with ovarian cancer know that it is an unpredictable, unkind, and often relentless disease. The quandary faced by oncologists in treating patients with ovarian cancer is analogous to William Shakespeare’s Hamlet, “whether it is nobler to suffer the slings and arrows of outrageous fortune Or to take arms against a sea of troubles and by opposing end them”
